- 02/19/2019 Iria has been granted a Phase I SBIR award by National Institute of Health (NIH) to further develop the ATTACK technology for triple negative cancer treatment！
- 05/21/2018 Iria has been granted a Phase I SBIR award by National Science Foundation (NSF) to further develop the ATTACK technology！
- 05/16/2017 Iria presents a fast pitch at 2017 Midwest University Health Technology Showcase in Chicago.
- 04/24/2017 Iria presents a fast pitch at 2017 iBIO IndEx in Chicago.
- 03/15/2017 Iria team graduates from the Illinois I-Corp Site Program.
- 02/15/2017 Our ATTACK technology is highlighted by C&EN News and is commented to have “potential advantages over antibody-drug conjugates”!
- 02/13/2017 Iria’s cancer targeting technology, ATTACK, is published online in Nature Chemical Biology.